Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2012 on request of the sponsor.
On 9 July 2003, orphan designation (EU/3/03/155) was granted by the European Commission to Cell Control Biomedical Laboratories AG, Germany, for murine anti-idiotypic antibody against OC125 antibody against CA125 antigen (ACA125) for the treatment of ovarian cancer.
The sponsorship was transferred to Menarini Ricerche S.p.A. in December 2004.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Key facts
Active substance |
Murine anti-idiotypic antibody against OC125 antibody against CA125 antigen
|
Intended use |
Treatment of ovarian cancer
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/03/155
|
Date of designation |
09/07/2003
|
Sponsor |
Menarini Ricerche S.p.A.
Via Tito Speri 10 00040 Pomezia (Roma) Italy Tel: +39 05 55 68 03 13 Fax +39 05 55 68 09 95 4 E-mail: abagovomab@menarini-ricerche.it |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: